Surveillance for Presumed BD-IPMN of the Pancreas: Stability, Size, and Age Identify Targets for Discontinuation.
Pancreas
Pancreatic Cancer
Pancreatic Cyst
Surveillance Discontinuation
Journal
Gastroenterology
ISSN: 1528-0012
Titre abrégé: Gastroenterology
Pays: United States
ID NLM: 0374630
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
received:
04
11
2022
revised:
11
06
2023
accepted:
14
06
2023
pmc-release:
01
10
2024
medline:
25
9
2023
pubmed:
6
7
2023
entrez:
5
7
2023
Statut:
ppublish
Résumé
Currently, most patients with branch duct intraductal papillary mucinous neoplasms (BD-IPMN) are offered indefinite surveillance, resulting in health care costs with questionable benefits regarding cancer prevention. This study sought to identify patients in whom the risk of cancer is equivalent to an age-matched population, thereby justifying discontinuation of surveillance. International multicenter study involving presumed BD-IPMN without worrisome features (WFs) or high-risk stigmata (HRS) at diagnosis who underwent surveillance. Clusters of individuals at risk for cancer development were defined according to cyst size and stability for at least 5 years, and age-matched controls were used for comparison using standardized incidence ratios (SIRs) for pancreatic cancer. Of 3844 patients with presumed BD-IPMN, 775 (20.2%) developed WFs and 68 (1.8%) HRS after a median surveillance of 53 (interquartile range 53) months. Some 164 patients (4.3%) underwent surgery. Of the overall cohort, 1617 patients (42%) remained stable without developing WFs or HRS for at least 5 years. In patients 75 years or older, the SIR was 1.12 (95% CI, 0.23-3.39), and in patients 65 years or older with stable lesions smaller than 15 mm in diameter after 5 years, the SIR was 0.95 (95% CI, 0.11-3.42). The all-cause mortality for patients who did not develop WFs or HRS for at least 5 years was 4.9% (n = 79), and the disease-specific mortality was 0.3% (n = 5). The risk of developing pancreatic malignancy in presumed BD-IPMN without WFs or HRS after 5 years of surveillance is comparable to that of the general population depending on cyst size and patient age. Surveillance discontinuation could be justified after 5 years of stability in patients older than 75 years with cysts <30 mm, and in patients 65 years or older who have cysts ≤15 mm.
Sections du résumé
BACKGROUND & AIMS
Currently, most patients with branch duct intraductal papillary mucinous neoplasms (BD-IPMN) are offered indefinite surveillance, resulting in health care costs with questionable benefits regarding cancer prevention. This study sought to identify patients in whom the risk of cancer is equivalent to an age-matched population, thereby justifying discontinuation of surveillance.
METHODS
International multicenter study involving presumed BD-IPMN without worrisome features (WFs) or high-risk stigmata (HRS) at diagnosis who underwent surveillance. Clusters of individuals at risk for cancer development were defined according to cyst size and stability for at least 5 years, and age-matched controls were used for comparison using standardized incidence ratios (SIRs) for pancreatic cancer.
RESULTS
Of 3844 patients with presumed BD-IPMN, 775 (20.2%) developed WFs and 68 (1.8%) HRS after a median surveillance of 53 (interquartile range 53) months. Some 164 patients (4.3%) underwent surgery. Of the overall cohort, 1617 patients (42%) remained stable without developing WFs or HRS for at least 5 years. In patients 75 years or older, the SIR was 1.12 (95% CI, 0.23-3.39), and in patients 65 years or older with stable lesions smaller than 15 mm in diameter after 5 years, the SIR was 0.95 (95% CI, 0.11-3.42). The all-cause mortality for patients who did not develop WFs or HRS for at least 5 years was 4.9% (n = 79), and the disease-specific mortality was 0.3% (n = 5).
CONCLUSIONS
The risk of developing pancreatic malignancy in presumed BD-IPMN without WFs or HRS after 5 years of surveillance is comparable to that of the general population depending on cyst size and patient age. Surveillance discontinuation could be justified after 5 years of stability in patients older than 75 years with cysts <30 mm, and in patients 65 years or older who have cysts ≤15 mm.
Identifiants
pubmed: 37406887
pii: S0016-5085(23)00935-6
doi: 10.1053/j.gastro.2023.06.022
pmc: PMC10548445
mid: NIHMS1931415
pii:
doi:
Types de publication
Multicenter Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1016-1024.e5Subventions
Organisme : NCI NIH HHS
ID : P50 CA062924
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2023 AGA Institute. Published by Elsevier Inc. All rights reserved.
Références
JAMA Surg. 2021 Jul 1;156(7):654-661
pubmed: 34009303
Gut. 2018 May;67(5):789-804
pubmed: 29574408
Pancreatology. 2020 Sep;20(6):1213-1217
pubmed: 32819844
Ann Surg. 2018 Jan;267(1):157-163
pubmed: 28079542
JAMA Surg. 2021 Sep 1;156(9):818-825
pubmed: 34009233
Pancreatology. 2012 May-Jun;12(3):183-97
pubmed: 22687371
Gut. 2018 Sep;67(9):1652-1662
pubmed: 29500184
Dig Surg. 2021;38(4):316-322
pubmed: 34515103
Pancreatology. 2017 Sep - Oct;17(5):738-753
pubmed: 28735806
Ann Surg. 2016 Jan;263(1):162-77
pubmed: 25775066
Ann Surg Oncol. 2018 Jun;25(6):1746-1751
pubmed: 29560572
Br J Surg. 2022 Jun 14;109(7):617-622
pubmed: 35511697
Gastroenterology. 2015 Apr;148(4):819-22; quize12-3
pubmed: 25805375
Am J Gastroenterol. 2019 Oct;114(10):1678-1684
pubmed: 31449158
Dig Liver Dis. 2020 May;52(5):547-554
pubmed: 32122771
Surgery. 2020 Oct;168(4):601-609
pubmed: 32739138
Gastroenterology. 2018 Feb;154(3):576-584
pubmed: 29074452
Pancreatology. 2019 Jan;19(1):2-9
pubmed: 30503370
J Am Coll Radiol. 2021 Oct;18(10):1405-1414
pubmed: 34174205
Ann Surg. 2022 Dec 1;276(6):1029-1038
pubmed: 33630454
Gastroenterology. 2020 Jan;158(1):226-237.e5
pubmed: 31473224
Pancreas. 2021 Oct 1;50(9):1287-1292
pubmed: 34860813
BJS Open. 2022 May 2;6(3):
pubmed: 35713028
Pancreatology. 2020 Apr;20(3):505-510
pubmed: 31948794
Pancreatology. 2010;10(2-3):144-50
pubmed: 20484954
Pancreatology. 2021 Jan;21(1):144-154
pubmed: 33309223
Gastroenterology. 2017 Nov;153(5):1284-1294.e1
pubmed: 28739282
Med Care. 2016 Feb;54(2):188-94
pubmed: 26683778
Am J Surg Pathol. 2015 Dec;39(12):1730-41
pubmed: 26559377
Gastroenterology. 2019 Oct;157(4):1123-1137.e22
pubmed: 31175866
J Hepatobiliary Pancreat Sci. 2021 Feb;28(2):131-142
pubmed: 33283481
Gut. 2018 Jan;67(1):138-145
pubmed: 28877981
Clin Transl Gastroenterol. 2022 Mar 28;13(3):e00463
pubmed: 35142721
Ann Surg. 2020 Dec;272(6):1118-1124
pubmed: 30672797
Medicine (Baltimore). 2016 Dec;95(51):e5535
pubmed: 28002329
Pancreas. 2011 May;40(4):571-80
pubmed: 21499212
Pancreatology. 2006;6(1-2):17-32
pubmed: 16327281
Int J Surg. 2014 Dec;12(12):1495-9
pubmed: 25046131
Surgery. 2012 Sep;152(3 Suppl 1):S135-42
pubmed: 22766364